Modality
Degrader
MOA
MALT1i
Target
TYK2
Pathway
PI3K/AKT
Bladder Ca
Development Pipeline
Preclinical
~Sep 2015
→ ~Dec 2016
Phase 1
~Mar 2017
→ ~Jun 2018
Phase 2
~Sep 2018
→ ~Dec 2019
Phase 3
Mar 2020
→ Aug 2028
Phase 3Current
NCT07945379
2,414 pts·Bladder Ca
2021-06→2026-08·Terminated
NCT06484051
1,738 pts·Bladder Ca
2025-04→TBD·Not yet recruiting
NCT08296039
1,789 pts·Bladder Ca
2020-03→2028-08·Not yet recruiting
+1 more trial
7,253 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2026-04-022d awayPh3 Readout· Bladder Ca
2026-08-215mo awayPh3 Readout· Bladder Ca
2026-10-106mo awayBTD· Bladder Ca
2028-08-032.3y awayPh3 Readout· Bladder Ca
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P3
Not yet…
P3
Termina…
P3
Recruit…
P3
Not yet…
Catalysts
Ph3 Readout
2026-04-02 · 2d away
Bladder Ca
Ph3 Readout
2026-08-21 · 5mo away
Bladder Ca
BTD
2026-10-10 · 6mo away
Bladder Ca
Ph3 Readout
2028-08-03 · 2.3y away
Bladder Ca
RecruitingTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07945379 | Phase 3 | Bladder Ca | Terminated | 2414 | HbA1c |
| NCT06484051 | Phase 3 | Bladder Ca | Not yet recr... | 1738 | eGFR |
| NCT08296039 | Phase 3 | Bladder Ca | Not yet recr... | 1789 | BodyWt |
| NCT06884875 | Phase 3 | Bladder Ca | Recruiting | 1312 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| ITC-6153 | Intra-Cellular | Phase 3 | KRASG12C | |
| Gelisertib | Samsung Biologics | Approved | IL-23 |